ESTABLISHING NEW STRATEGIES IN AF DETECTION

Make the LINQ between atrial fibrillation and stroke for patients at high risk.
AF + STROKE
A GLOBAL HEALTH CHALLENGE

1 IN 4
OF ALL STROKES
ARE CAUSED BY AF

15 MILLION
PEOPLE
WORLDWIDE
EXPERIENCE A STROKE
EACH YEAR

AF DETECTION
AND TREATMENT MATTERS

5-FOLD
increase in ischemic stroke risk for AF patients.

1/5th
of patient symptoms thought to be AF were actually due to AF.

67%
decrease in AF patient stroke risk with oral anticoagulants.

2X
more likely for AF-related ischemic stroke to be fatal as non-AF stroke.

~90%
of AF episodes may be asymptomatic.

15 MILLION
PEOPLE
WORLDWIDE
EXPERIENCE A STROKE
EACH YEAR

DIFFICULTIES IN
AF DETECTION

Symptoms are not a reliable indicator of AF.

~90%
of AF episodes may be asymptomatic.

1/5th
of patient symptoms thought to be AF were actually due to AF.

STROKE

Short-term and intermittent cardiac monitoring may miss many patients with paroxysmal AF

- Short-term monitoring via 24-hour Holter has low sensitivity and negative predictive value for AF detection.
- Intermittent and symptom-based monitoring has a significantly lower sensitivity and negative predictive value for AF detection compared with continuous monitoring.

Longer, continuous monitoring periods result in higher AF detection.

1 IN 4
OF ALL STROKES
ARE CAUSED BY AF

15 MILLION
PEOPLE
WORLDWIDE
EXPERIENCE A STROKE
EACH YEAR

AF DETECTION
AND TREATMENT MATTERS

5-FOLD
increase in ischemic stroke risk for AF patients.

1/5th
of patient symptoms thought to be AF were actually due to AF.

67%
decrease in AF patient stroke risk with oral anticoagulants.

2X
more likely for AF-related ischemic stroke to be fatal as non-AF stroke.

~90%
of AF episodes may be asymptomatic.
Prospective, global, multicenter study
- 446 patients enrolled, 385 patients received a Reveal™ ICM and were included in the analysis cohort
- Patients were followed for an average of 22.5 months + 7.7 months

A CHADS² score of ≥ 3 or CHADS² = 2 and at least 1 of the following:
- Coronary artery disease
- Renal impairment (GFR 30-60 ml/min)
- Sleep apnea
- Chronic obstructive pulmonary disease

No AF found after 24 hours of cardiac monitoring.

Primary
Determine the incidence rate of AF lasting ≥ 6 minutes in patients who are at high risk of having AF and stroke.

Secondary
- Identify predictors of AF onset
- Characterize the timing and nature of clinical actions relative to detection of AF

The Reveal AF study may have important implications for prophylactic AF screening and treatment in high-risk patients.⁹

Visit medtronic.com/RevealAF for complete study information.
INFORM YOUR CLINICAL DECISIONS

New strategies for patients at high risk for AF and stroke

AF incidence by CHADS\textsubscript{2} subgroup\textsuperscript{9}

REVEAL AF STUDY SECONDARY END POINTS

AF detected through Reveal ICM was found to be actionable by physicians.\textsuperscript{9}

56.3\% of patients were prescribed oral anticoagulants during follow-up.\textsuperscript{9}

14.8\% of patients were prescribed rhythm-control medication during follow-up.\textsuperscript{9}

There was no significant difference in detection rates between patients with CHADS\textsubscript{2} 2, 3, and 4 or more.\textsuperscript{9}

AN ADVANCED MONITORING SOLUTION

Reveal LINQ ICM

MyCareLink\textsuperscript{™} Patient Monitor

CareLink\textsuperscript{™} Network and Reports

There was no significant difference in detection rates between patients with CHADS\textsubscript{2} 2, 3, and 4 or more.\textsuperscript{9}

AF detected through Reveal ICM was found to be actionable by physicians.\textsuperscript{9}

56.3\% of patients were prescribed oral anticoagulants during follow-up.\textsuperscript{9}

14.8\% of patients were prescribed rhythm-control medication during follow-up.\textsuperscript{9}
UNMATCHED ACCURACY

DRIVING ACCURACY EVOLUTION
Dedicated to advancing accuracy with every device generation.

INDUSTRY-LEADING TRURHYTHM DETECTION
Our newest detection algorithms streamline episode review without sacrificing sensitivity.

SUPERIOR ACCURACY IN AF DETECTION
Demonstrating superior atrial fibrillation detection accuracy through our performance results.

Advanced AF detection*  
<table>
<thead>
<tr>
<th>Algorithm</th>
<th>Sensitivity</th>
<th>PPV</th>
</tr>
</thead>
<tbody>
<tr>
<td>Reveal LINQ™</td>
<td>98.9%</td>
<td>99.0%</td>
</tr>
<tr>
<td>Confirm™ ICM</td>
<td>83.9%</td>
<td>97.3%</td>
</tr>
</tbody>
</table>

AF BURDEN

<table>
<thead>
<tr>
<th>Algorithm</th>
<th>Sensitivity</th>
<th>PPV</th>
</tr>
</thead>
<tbody>
<tr>
<td>Reveal LINQ™</td>
<td>99.7%</td>
<td>95.3%</td>
</tr>
<tr>
<td>Confirm™ ICM</td>
<td>94.0%</td>
<td>59.1%</td>
</tr>
</tbody>
</table>

AF EPISODE

<table>
<thead>
<tr>
<th>Algorithm</th>
<th>Sensitivity</th>
<th>PPV</th>
</tr>
</thead>
<tbody>
<tr>
<td>Reveal LINQ™</td>
<td>99.7%</td>
<td>95.3%</td>
</tr>
<tr>
<td>Confirm™ ICM</td>
<td>94.0%</td>
<td>59.1%</td>
</tr>
</tbody>
</table>

† In known AF patients.

Streamlined Episode Review

AF False Positive %

- Confirm-AF®: 39.3%
- BioMonitor 2-AF™: 26.3%
- Reveal LINQ™: 9.6%
- Reveal LINQ with TruRhythm Detection®: 4.7%

8X more false positives shown by other ICM.10,11

10 More false positives shown by other ICM compared to Reveal LINQ.
11 More false positives shown by other ICM compared to Reveal LINQ with TruRhythm Detection.

* In known AF patients.
AF is often paroxysmal and difficult to detect with traditional monitoring modalities.\textsuperscript{5-8}

~90% of AF episodes may be asymptomatic.\textsuperscript{5}

STROKE is the first symptom for ~20% of patients who have an AF-related stroke.\textsuperscript{3}

REVEAL AF STUDY
Demonstrating the need for long-term, continuous cardiac monitoring for patients at high risk for AF and stroke.\textsuperscript{9}

medtronic.com/RevealAF

40% AF detection rate at 30 months.\textsuperscript{9}

123 days was the median time to AF detection in high-risk patients.\textsuperscript{9}

84.5% of patients with AF would have been missed if only monitored for 30 days.\textsuperscript{9}